Sector News

GlobeImmune CEO steps down as partnership with Gilead fizzles

November 21, 2016
Life sciences

GlobeImmune has been struggling for some time, and its Nov. 18 updates effectively ward off investor hopes for a turnaround in the near term.

In June 2015, the company initiated a strategic review in the hopes of finding a transaction to lift the business. In conjunction with that announcement, GlobeImmune cut the bulk of its workforce to provide enough cash to continue operations.

The review, which ended earlier this year, never yielded any transaction.

The biopharma has kept mostly quiet since July, when it delisted from the NASDAQ and moved over to the OTC Pink stock market. In its last quarterly filing with the Securities and Exchange Commission, GlobeImmune reported $8.7 million in cash and cash equivalents as of March 31, which comprised 89% of its total assets. GlobeImmune also reported $7.6 million in liabilities.

In a release, the company cited “ongoing listing, legal, administrative and additional accounting costs,” an “inordinate amount of executive time and Company resources consumed in regulatory compliance obligations,” and a “lack of investor interest as shown in the low daily trading volumes of the Common Stock on NASDAQ,” as reasons for the delisting.

From Gilead’s end, the Food and Drug Administration’s approval of hep B drug Vemlidy earlier this month likely made it easier to separate ties with GlobeImmune. Still, the pharmaceutical heavyweight has seen revenues from its antiviral portfolio shrink as of late. Global sales of those products shrunk more than 10% — from $7.7 billion to $6.8 billion — between the third quarter of 2015 and the same period this year.

GlobeImmune did not disclose any potential replacements for Rodell.

Company shares traded at 50 cents Friday morning, down 28%.

By Jacob Bell

Source: BioPharmaDive

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach